Cooley

Rama Padmanabhan

Deals
4
Latest
Sep 2026
Most deals in
Biotech

Firm

  • Cooley Law firm · 2026 · 4 deals
Deals by year
Rama Padmanabhan: deals by year0123420252026 YTD: 3 M&A2026 YTD: 1 Equity raisings42026 YTDM&AEquity raisings

Often works with

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deals Rama Padmanabhan was named on, most recent first
Sep 2026 trispecific T cell-engager (TCE) asset Chimagen BiosciencesGSKAsset saleLegal adviser to Chimagen Biosciences (seller)Announced750.0Biotech+2GSK acquisition of trispecific T cell-engager (TCE) asset
May 2026 Vaccine Company –LillyAcquisitionLegal adviser to Vaccine Company (target)Announced1,550.0Biotech+1Lilly acquisition of Vaccine Company
May 2026 Candid Therapeutics –UCBAcquisitionLegal adviser to Candid Therapeutics (target)Announced2,200.0Biotech+1UCB acquisition of Candid Therapeutics
Mar 2026 Candid Therapeutics ––PlacementLegal adviser to the issuerPending505.0Biotech+1Candid Therapeutics placement

Deals where Rama Padmanabhan is named on the firm's deal team, by the firm or the press.

Suggest a correction

A missing deal, a wrong firm, a move between firms, or two different people shown as one. A link to a public source helps.